Osmol Therapeutics is developing OSM-0205, an intravenous treatment designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) and cognitive impairment (CICI) by targeting calcium surge interactions that lead to neuronal damage. This approach aims to enhance chemotherapy dosing and improve patient outcomes for those at risk of debilitating side effects from taxane-based therapies.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients undergoing taxane-based chemotherapy develop chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), debilitating conditions for which there are currently no effective treatments. These side effects often force clinicians to reduce chemotherapy dosages, potentially leading to suboptimal cancer treatment outcomes.
Solution
Osmol Therapeutics is developing OSM-0205, an intravenous treatment designed to prevent CIPN and CICI by targeting the calcium surge interaction that initiates neuronal damage. Administered just before chemotherapy, OSM-0205 aims to prevent the cascade of neuronal damage, allowing patients to receive optimal chemotherapy dosing without the risk of severe side effects. This approach focuses on both physical and cognitive well-being, offering a promising path to enhanced patient outcomes.
Target Audience
The primary target audience includes cancer patients at risk of developing CIPN and CICI as a result of taxane-based chemotherapy, as well as oncologists seeking to improve patient outcomes and quality of life during cancer treatment.
Features
- Intravenous administration prior to chemotherapy sessions
- Targets the calcium surge interaction to prevent neuronal damage
- Designed to prevent both CIPN and CICI
- Aims to allow for optimal chemotherapy dosing without debilitating side effects